Oyovwi Mega Obukohwo, Udi Onoriode Andrew, Atere Adedeji David, Joseph Gregory Uchechukwu, Ogbutor Udoji Godsday
Department of Physiology, Faculty of Basic Medical Sciences, Adeleke University, Ede, Osun State, Nigeria.
Department of Human Anatomy, Federal University Otuoke, Yenagoa, Bayelsa State, Nigeria.
Mol Biol Rep. 2025 Feb 17;52(1):240. doi: 10.1007/s11033-025-10349-x.
Neurodegenerative diseases like Parkinson's and Alzheimer's are a global health challenge due to their progressive degeneration, leading to cognitive decline and motor dysfunction. Monoamine oxidase B (MAO-B) enzyme is implicated in neurodegeneration, and developing inhibitors could be a promising therapeutic strategy. This review explores MAO-B activity molecular pathways, evaluates MAO-B inhibitors in neurodegenerative therapy, identifies challenges, and suggests future research directions. This review synthesizes findings from a range of scientific literature, including experimental studies, clinical trials, and biochemical analyses that focus on the role of MAO-B in neurodegeneration. Information was gathered from databases such as PubMed, Scopus, and Web of Science, ensuring a comprehensive overview of recent advancements in MAO-B inhibition strategies. The review reveals several promising MAO-B inhibitors that have demonstrated efficacy in preclinical models, as well as some that have progressed to clinical trials. Compounds such as rasagiline and selegiline have shown neuroprotective effects and benefits in symptom management in patients with Parkinson's disease. Furthermore, the review discusses novel inhibitors that target specific molecular pathways, enhancing the potential for improved therapeutic outcomes. However, several inhibitors also present challenges regarding their selectivity, side effects, and long-term efficacy. Research on MAO-B inhibitors for neurodegenerative diseases is crucial, with ongoing studies aiming for selective, potent molecules with fewer side effects and multimodal therapies.
帕金森病和阿尔茨海默病等神经退行性疾病是一项全球性的健康挑战，因为它们会逐渐退化，导致认知能力下降和运动功能障碍。单胺氧化酶B（MAO-B）与神经退行性变有关，开发其抑制剂可能是一种有前景的治疗策略。本综述探讨了MAO-B活性的分子途径，评估了MAO-B抑制剂在神经退行性疾病治疗中的作用，确定了挑战，并提出了未来的研究方向。本综述综合了一系列科学文献的研究结果，包括专注于MAO-B在神经退行性变中作用的实验研究、临床试验和生化分析。信息是从PubMed、Scopus和Web of Science等数据库收集的，以确保全面概述MAO-B抑制策略的最新进展。该综述揭示了几种在临床前模型中已显示出疗效的有前景的MAO-B抑制剂，以及一些已进入临床试验阶段的抑制剂。雷沙吉兰和司来吉兰等化合物已在帕金森病患者的症状管理中显示出神经保护作用和益处。此外，该综述还讨论了针对特定分子途径的新型抑制剂，增强了改善治疗效果的潜力。然而，一些抑制剂在选择性、副作用和长期疗效方面也存在挑战。对神经退行性疾病的MAO-B抑制剂的研究至关重要，正在进行的研究旨在寻找具有更少副作用的选择性、强效分子以及多模式治疗方法。
